After careful review and discussion, the DCAT Board of Directors determined that an amendment to the organization’s current bylaws was required. During its May 22, 2018 DCAT Board of Directors meeting held in New York City, the Board voted to amend Article VIII, Section 1 of DCAT’s bylaws. By amending the section with the language as specified below in yellow, the board provided the ability to suspend an article and/or related section(s) thus providing the needed time to define, clarify, develop, and implement initiatives that can best support and further the overall mission of the organization.
ARTICLE VIII. MISCELLANEOUS
Section 1. Amendments to the Bylaws. Amendments to these bylaws are made by a two-thirds vote of the Board of Directors provided they are given 60 days notice of the proposed changes, rationale and an opportunity to comment. At any meeting of the Board of Directors, where a quorum is present, the Board may, by majority vote, suspend an Article and/or related Section(s) of the bylaws in order to better define, clarify, restructure and/or generally strengthen the organizational guidelines. Suspension of an Article and/ or related Section(s) cannot be suspended for more than 12 months. All changes to the bylaws will be posted on the organization’s website in a conspicuous manner within 10 days of the change.
Subsequent Decision: After the adoption of this change, the Board voted to suspend the application and election process for six (6) new members for the Advisory Council as outlined in Article VI, Section 5 and Section 5.b of the bylaws for the upcoming fiscal year beginning November 1, 2018.
Rationale: The Board has a renewed focus on governance which includes improving the leadership structure, enhancing a volunteer’s experience, as well as identifying and developing future leaders. They are examining the following:
Click here to read the full text of DCAT's Bylaws.
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.